Wolverine Trading
VIRX

Wolverine Trading’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Wolverine Trading’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-3,029
Closed -$14K – 5619
2020
Q3 		$14K Buy
3,029
+2,600
+606% +$22.7K ﹤0.01% 4401
2020
Q2 		$4K Sell
429
-165
-28% -$2.49K ﹤0.01% 4473
2020
Q1 		$9K Buy
+594
New +$12.9K ﹤0.01% 4493
2018
Q4 		– Sell
-1,394
Closed -$98K – 5522
2018
Q3 		$98K Buy
1,394
+985
+241% +$74.8K ﹤0.01% 4552
2018
Q2 		$39K Hold
409
– – ﹤0.01% 4949
2018
Q1 		$39K Sell
409
-160
-28% -$27.4K ﹤0.01% 4949
2017
Q4 		$73K Buy
+569
New +$53.3K ﹤0.01% 4534
2017
Q3 		– Sell
-303
Closed -$29K – 5185
2017
Q2 		$29K Sell
303
-51
-14% -$5.86K ﹤0.01% 4129
2017
Q1 		$51K Sell
354
-537
-60% -$76.8K ﹤0.01% 3996
2016
Q4 		$113K Sell
891
-106
-11% -$14.8K ﹤0.01% 4017
2016
Q3 		$151K Buy
997
+938
+1,590% +$132K ﹤0.01% 3991
2016
Q2 		$7K Buy
+59
New +$6.54K ﹤0.01% 3940

Other funds holding VIRX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wolverine Trading's VIRX Position: Q3 2020 in Review

Wolverine Trading sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q3 2020, closing a stake of 340 shares — an estimated $2.97K sold.

Wolverine Trading first reported a position in VIRX in Q2 2016 and held it in 8 quarters. The position peaked at $59K in Q1 2017. 28 funds tracked by Wall St. Rank hold VIRX as of Q3 2020.

  • Wolverine Trading reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • Wolverine Trading sold 340 Viracta Therapeutics, Inc. Common Stock shares in Q3 2020, an estimated $2.97K.
  • Wolverine Trading first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2016 and held it in 8 quarters.
  • Wolverine Trading's Viracta Therapeutics, Inc. Common Stock position peaked at $59K in Q1 2017.
  • 28 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q3 2020.

Based on Wolverine Trading's 13F filing for Q3 2020, filed 13 Nov 2020.